HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PP242

inhibits MTOR protein; structure in first source

Networked: 72 relevant articles (3 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - PP242: 72
    - Indoles: 200
      - PP242: 72

Experts

1.	Shokat, Kevan M: 4 articles (01/2020 - 03/2010)
2.	Gera, Joseph: 4 articles (07/2016 - 06/2012)
3.	Goncharova, Elena A: 3 articles (11/2017 - 02/2014)
4.	Lichtenstein, Alan: 3 articles (07/2016 - 06/2012)
5.	Cheng, Lei: 2 articles (08/2021 - 01/2015)
6.	Hu, Jing: 2 articles (08/2021 - 01/2015)
7.	Qian, Xiaoping: 2 articles (08/2021 - 01/2015)
8.	Cowley, Allen W: 2 articles (01/2021 - 01/2019)
9.	Kumar, Vikash: 2 articles (01/2021 - 01/2019)
10.	Kurth, Theresa: 2 articles (01/2021 - 01/2019)

Related Diseases

1.	Vascular Remodeling 11/01/2017 - "PP242 reversed pulmonary vascular remodeling and prevented neointimal occlusion of small PAs, significantly reduced PA pressure and pulmonary vascular resistance, reversed cardiomyocyte hypertrophy and RV remodeling, improved max RV contractility, arterial elastance, and RV acceleration time, and prevented development of RV fibrosis. " 02/25/2014 - "Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats. "
2.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2018 - "Altogether, our results reveal that combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells." 01/01/2021 - "In spite of the promising in vitro and preclinical results, dual PI3K/Akt/mTOR inhibitor NVP-BEZ235, and ATP-competitive mTOR inhibitor PP242 both failed to confirm their inhibitory efficacy against renal cell carcinoma (RCC) in clinical settings. " 01/01/2018 - "However, PP242 (inhibitor of mTORC1 and mTORC2) alone did not induce human renal carcinoma cell death. "
3.	Macular Degeneration (Age-Related Maculopathy) 11/30/2023 - "Here, we validated the therapeutic efficacy of the mTOR inhibitors, Torin and PP242, in clearing amyloid-β by inducing the autophagy-lysosome pathway in a mouse model with pathogenic amyloid-β with tight junction disruption of RPE, which is evident in dry age-related macular degeneration. "
4.	Hypertrophy 11/01/2017 - "PP242 reversed pulmonary vascular remodeling and prevented neointimal occlusion of small PAs, significantly reduced PA pressure and pulmonary vascular resistance, reversed cardiomyocyte hypertrophy and RV remodeling, improved max RV contractility, arterial elastance, and RV acceleration time, and prevented development of RV fibrosis. "
5.	Fibrosis (Cirrhosis) 11/01/2017 - "PP242 reversed pulmonary vascular remodeling and prevented neointimal occlusion of small PAs, significantly reduced PA pressure and pulmonary vascular resistance, reversed cardiomyocyte hypertrophy and RV remodeling, improved max RV contractility, arterial elastance, and RV acceleration time, and prevented development of RV fibrosis. "

Related Drugs and Biologics

1.	MTOR Inhibitors
2.	Adenosine Triphosphate (ATP)
3.	dactolisib
4.	Amyloid (Amyloid Fibrils)
5.	torin
6.	Sirolimus (Rapamycin)
7.	Mechanistic Target of Rapamycin Complex 1
8.	Mechanistic Target of Rapamycin Complex 2
9.	Phosphotransferases (Kinase)
10.	TOR Serine-Threonine Kinases

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Aftercare (After-Treatment)
4.	Molecular Targeted Therapy